Viking Therapeutics (VKTX) announced that results from the company’s Phase 2b clinical trial of VK2809, the company’s novel liver-selective thyroid hormone receptor beta agonist, in patients with ...

Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or ...

On Friday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $49.58 which represents a decrease of $-3.99 or -7.45% from the prior close of $53.57. The stock opened at $53.18 and ...

There aren't many biotechs that are more exciting than Viking Therapeutics (NASDAQ: VKTX) right now. Thanks to its ...

Equity markets have performed well in 2024, but their showing pales next to that of Viking Therapeutics (NASDAQ: VKTX), a mid ...

The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr.

Los Angeles Capital Management LLC trimmed its holdings in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by ...

On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $60.6 which represents a decrease of $-2.37 or -3.76% from the prior close of $62.97. The stock opened at $62.46 and ...

A small player like Viking may also win by attracting a partner or even a company that will offer to acquire the biotech.

With a gain of more than 531% over the last 12 months, shares of Viking Therapeutics (NASDAQ: VKTX) are a hot commodity, to ...

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock ...